Education
About Us
Working with TipRanks
Follow Us
Bio-Techne (TECH)
NASDAQ:TECH
Top Page
Bio-Techne
(NASDAQ:TECH)
Rating:72Outperform
Price Target:
$57.00
▲(14.27%Upside)
Positive Factors
Financial Performance
Bio-Techne reported better-than-expected financial results for their 3Q25, including revenues of $316.2 million, an increase of 4.2% year-over-year, and increased adjusted earnings of $0.56 as compared to $0.48 one year ago.
Investment Opportunity
The recent pullback in TECH's share price offers a compelling entry point as it trades below its historical average, indicating an attractive investment opportunity.
Portfolio and Growth
TECH is well-positioned to sustainably generate above-market organic growth due to its differentiated portfolio and exposure to high-growth verticals.
Negative Factors
Market Exposure
TECH has exposure to US ACA/government end-market, which has weighed heavily on the stock.
Tariffs and Market Impact
Company management was somewhat cautious in providing forward guidance for 4Q25E, due to uncertainties related to US government spending on R&D programs and the impact of tariffs on China and other international markets.
Bio-Techne (TECH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.63B
Dividend Yield0.66%
Average Volume (3M)2.44M
Price to Earnings (P/E)59.3
Beta (1Y)0.94
Revenue Growth4.72%
EPS Growth-35.33%
CountryUS
Employees3,100
SectorHealthcare
Sector Strength42
IndustryBiotechnology
Share Statistics
EPS (TTM)0.56
Shares Outstanding156,767,290
10 Day Avg. Volume2,737,911
30 Day Avg. Volume2,444,079
Financial Highlights & Ratios
PEG Ratio9.51
Price to Book (P/B)3.81
Price to Sales (P/S)0.00
P/FCF Ratio31.05
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue1.73
Enterprise Value/Gross Profit10.31
Enterprise Value/Ebitda5.70
Forecast
1Y Price Target
$68.80Price Target Upside37.93% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Bio-Techne Business Overview & Revenue Model
Company DescriptionBio-Techne Corporation (TECH) is a leading developer and manufacturer of high-quality biotechnology products and solutions. The company operates in the life sciences sector, focusing on providing innovative tools and reagents to researchers and clinicians worldwide. Bio-Techne's core offerings include proteins, antibodies, immunoassays, and instruments used in scientific research, diagnostics, and therapeutic development.
How the Company Makes MoneyBio-Techne makes money primarily through the sale of its diverse range of biotechnology products and solutions. Key revenue streams include sales of proteins and antibodies, which are essential components for research and development in life sciences. The company also generates significant income from its immunoassay and diagnostic products, which are widely used in clinical settings to detect and quantify biological markers. Additionally, Bio-Techne benefits from partnerships and collaborations with academic institutions, research organizations, and pharmaceutical companies, enhancing its market reach and contributing to its earnings.
Bio-Techne Earnings Call Summary
Earnings Call Date:May 07, 2025
(Q3-2025)
| % Change Since: 4.70%|
Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment Neutral
Bio-Techne reported strong organic revenue growth and a solid financial position with significant achievements in the pharma and diagnostics segments. However, challenges such as NIH funding uncertainty, tariff impacts, and difficulties in the China market present notable headwinds. The company's strategies to mitigate these challenges are promising, yet the timing and full impact remain uncertain.Q3-2025 Updates
Positive Updates
Strong Organic Revenue Growth
Bio-Techne reported 6% organic revenue growth in a challenging macro environment, with a focus on profitability leading to an adjusted operating margin of 34.9%.
Pharma Segment Performance
The pharma segment showed low double-digit growth, driven by improved R&D pipelines and strong demand in the Protein Sciences segment with 7% organic revenue growth.
Protein Analytical Instrument Growth
The protein analytical instrumentation business, particularly the biologics platform Maurice, experienced double-digit growth driven by strong demand from pharma and CRO partners.
Diagnostics Growth
Year-to-date growth in diagnostic reagents was in the high-single digits, and the Asuragen portfolio saw low double-digit growth. The ExoDx prostate cancer test increased over 30% for the fiscal year-to-date.
Tariff Mitigation Strategies
Despite tariff challenges, Bio-Techne is well-positioned to mitigate impacts through optimization of global production and supply chain strategies, with expected full mitigation by the start of fiscal 2026.
Strong Financial Position
Bio-Techne reported $41.1 million in cash generated from operations, returned $12.6 million in dividends, and executed $100 million in stock buybacks. The company maintains a strong balance sheet with a total leverage ratio well below one time EBITDA.
Negative Updates
NIH Funding Uncertainty
US academic customers face uncertainty due to potential NIH funding cuts, impacting purchasing decisions, particularly around capital equipment.
Academic Market Challenges
The Spatial Biology segment, heavily exposed to US academic end markets, has been impacted by NIH funding uncertainty, affecting growth rates.
Tariff Challenges
Recent increases in global tariffs present a potential $20 million annual impact to adjusted operating income, with significant exposure from Chinese tariffs on proteomic analytical instruments.
China Market Decline
Revenue from China decreased mid-single digits due to ongoing economic challenges, contrasting with improved conditions in the rest of Asia.
Stalled Biotech Momentum
Momentum in the biotech sector has stalled due to global economic uncertainties, impacting growth expectations.
Company Guidance
During the third quarter of Fiscal Year 2025, Bio-Techne reported strong financial performance, with a 6% organic revenue growth and a 34.9% adjusted operating margin, despite a challenging macroeconomic environment. The company's growth was driven by low double-digit growth in the pharma sector, a 7% increase in the Protein Sciences segment, and a 2% growth in Diagnostics and Spatial Biology. The company also saw significant contributions from its GMP reagents, which grew at a high-single-digit rate, and its protein analytical instrumentation business. Bio-Techne's adjusted EPS rose to $0.56 from $0.48 in the previous year, with a GAAP EPS of $0.14. The company is strategically navigating challenges such as NIH funding uncertainties and tariff impacts, expecting full mitigation of tariff costs by the start of Fiscal Year 2026. Despite these challenges, Bio-Techne remains well-positioned for future growth, bolstered by its comprehensive product portfolio and strategic investments.Bio-Techne Financial Statement Overview
Summary
Bio-Techne exhibits solid financial health with strong revenue growth and profitability. The balance sheet is stable with low debt levels, and cash flow remains robust. Despite some challenges in net profit margins and increasing debt, the company's overall financial position is strong, supporting continued growth and resilience in the biotechnology sector.Income Statement
Bio-Techne demonstrates strong revenue growth with a consistent upward trajectory over the years, evidenced by a 3.3% increase in revenue from 2023 to 2024 (TTM). The company maintains robust profitability with a gross profit margin of 65.8% and an EBIT margin of 19.9% for TTM. However, the net profit margin has decreased, reflecting a decline in net income, suggesting potential cost pressures or other operational challenges.85
Very Positive
Balance Sheet
The company maintains a healthy balance sheet with a Debt-to-Equity ratio of 0.18 in TTM, indicating low leverage and financial stability. The equity ratio stands at 78.2%, showcasing strong equity backing. However, there is a slight increase in total debt, which could pose a risk if not managed well.78
Positive
Cash Flow
Operating cash flow remains strong with a 1.93 ratio to net income in TTM, indicating efficient cash generation. Free cash flow shows growth, although at a slower pace compared to previous years. The company efficiently converts its earnings into cash flow, supporting its operational liquidity and investment activities.82
Very Positive
| Breakdown | |||||
| TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 1.20B | 1.16B | 1.14B | 1.11B | 931.03M | 738.69M | Gross Profit |
| 787.02M | 769.73M | 769.82M | 756.50M | 632.85M | 483.19M | EBIT |
| 238.38M | 206.69M | 298.94M | 296.59M | 149.55M | 74.68M | EBITDA |
| 344.88M | 310.37M | 460.56M | 420.12M | 258.47M | 373.91M | Net Income Common Stockholders |
| 158.14M | 168.10M | 285.26M | 272.05M | 140.41M | 229.30M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 145.31M | 152.86M | 204.31M | 247.03M | 231.55M | 270.89M | Total Assets |
| 2.72B | 2.70B | 2.64B | 2.29B | 2.26B | 2.03B | Total Debt |
| 494.73M | 419.54M | 454.96M | 325.97M | 420.55M | 433.53M | Net Debt |
| 354.81M | 267.75M | 274.39M | 153.40M | 221.46M | 286.90M | Total Liabilities |
| 706.79M | 635.02M | 672.18M | 593.79M | 691.72M | 646.40M | Stockholders Equity |
| 2.01B | 2.07B | 1.97B | 1.70B | 1.57B | 1.38B |
| Cash Flow | Free Cash Flow | ||||
| 254.30M | 236.10M | 216.15M | 280.36M | 307.86M | 153.47M | Operating Cash Flow |
| 304.72M | 298.98M | 254.39M | 325.27M | 352.16M | 205.22M | Investing Cash Flow |
| -51.97M | -203.03M | -265.65M | -96.85M | -243.52M | 27.09M | Financing Cash Flow |
| -207.92M | -122.40M | 22.62M | -242.85M | -62.55M | -183.80M |
Bio-Techne Technical Analysis
Negative
49.88
Price Trends
50.53
Negative
58.88
Negative
66.19
Negative
Market Momentum
-0.62
Negative
47.41
Neutral
65.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECH, the sentiment is Negative. The current price of 49.88 is above the 20-day moving average (MA) of 48.87, below the 50-day MA of 50.53, and below the 200-day MA of 66.19, indicating a bearish trend. The MACD of -0.62 indicates Negative momentum. The RSI at 47.41 is Neutral, neither overbought nor oversold. The STOCH value of 65.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECH.
Bio-Techne Risk Analysis
Bio-Techne disclosed 27 risk factors in its most recent earnings report. Bio-Techne reported the most risks in the “Production” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bio-Techne Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $13.31B | 216.24 | 0.47% | ― | 17.13% | -88.78% | |
72 Outperform | $7.63B | 59.35 | 6.53% | 0.66% | 4.72% | -35.33% | |
71 Outperform | $10.86B | 21.02 | 9.64% | ― | 17.99% | 152.10% | |
71 Outperform | $3.96B | 32.98 | 13.90% | ― | 247.53% | 118.34% | |
54 Neutral | $2.26B | ― | -31.51% | ― | ― | ― | |
54 Neutral | $5.31B | 3.28 | -45.10% | 2.80% | 16.76% | 0.02% | |
48 Neutral | $10.62B | ― | -29.34% | ― | -38.25% | 44.29% |
* Healthcare Sector Average
Performance Comparison
TECH
Bio-Techne
49.88
-26.84
-34.98%
BMRN
BioMarin Pharmaceutical
56.88
-26.06
-31.42%
INCY
Incyte
69.89
10.49
17.66%
KRYS
Krystal Biotech
136.08
-40.75
-23.04%
MRNA
Moderna
28.14
-120.45
-81.06%
NAMS
NewAmsterdam Pharma Company
20.16
0.48
2.44%
Bio-Techne Corporate Events
Business Operations and StrategyFinancial Disclosures
Bio-Techne Reports Q3 2025 Financial Results
Neutral
May 7, 2025
On May 7, 2025, Bio-Techne Corporation announced its financial results for the third quarter of fiscal 2025, reporting a 6% increase in organic revenue to $316.2 million. The company saw a decline in GAAP earnings per share to $0.14 from $0.31 a year ago, but adjusted EPS rose to $0.56. The Protein Sciences segment experienced 7% organic growth, driven by improved pharma market conditions and strong commercial execution. The adjusted operating margin increased to 34.9%, reflecting profitability initiatives and volume leverage. Despite a challenging macroenvironment, Bio-Techne’s strategic positioning and leadership are expected to help navigate current conditions, enhancing its financial performance and market presence.
Stock Buyback
Bio-Techne Announces New $500M Share Repurchase Program
Positive
May 6, 2025
On April 30, 2025, Bio-Techne Corporation’s Board of Directors authorized a new share repurchase program, allowing the company to buy back up to $500 million of its common stock. This program replaces the previous one from February 2022 and has no set time limit. The repurchases can be made through various methods, including open market and private transactions, and are subject to market conditions and the company’s financial performance. The initiative aims to manage stock dilution and optimize capital needs, with disclosures to be made in the company’s annual and quarterly reports.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.